The BRAF V600E mutation, a target for current molecular therapies, has previously been detected in various childhood tumours such as pleomorphic astrocytomas (66.7%), Langerhans cell histiocytosis (LCH) (57%) and low-grade gliomas [7–9]. Here, BRAF is linked to Langerhans cell histiocytosis.